Dalriada Therapeutics is a leading Canadian contract research organization specializing in small molecule drug discovery. Founded in 2017, it employs a unique Turn-Key™ model that integrates various drug discovery services, including target validation, hit identification, and lead optimization, under one roof. With a team of over 100 professionals, including more than 70% Ph.D. scientists, Dalriada has a proven track record of advancing compounds through the drug development pipeline. The company supports global biotechnology and pharmaceutical clients, providing them with state-of-the-art facilities and expertise to accelerate their drug discovery programs. Dalriada's commitment to innovation and collaboration positions it as a key player in the competitive landscape of drug discovery.
Something looks off?